ME4fdg | 915776-36-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ME4fdg
• 英文别名: (2S,3R,4R,5S,6R)-5-(18F)fluoranyl-6-(hydroxymethyl)-2-methoxyoxane-3,4-diol
• CAS: 915776-36-2
• 化学式: C7H13FO5
• 分子量: 195.18
• InChiKey: PGYKOSXDWWGTOB-XZWCPNKHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  79.2
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• SODIUM-DEPENDENT GLUCOSE TRANSPORTER 2 AS A DIAGNOSTIC AND THERAPEUTIC TARGET FOR PRE-MALIGNANT LESIONS
  申请人：The Regents of the University of California

  公开号：EP4003432A1

  公开（公告）日：2022-06-01
• [EN] SODIUM-DEPENDENT GLUCOSE TRANSPORTER 2 AS A DIAGNOSTIC AND THERAPEUTIC TARGET FOR PRE-MALIGNANT LESIONS<br/>[FR] TRANSPORTEUR DE GLUCOSE DÉPENDANT DU SODIUM, DE TYPE 2, EN TANT QUE CIBLE DIAGNOSTIQUE ET THÉRAPEUTIQUE POUR DES LÉSIONS PRÉ-MALIGNES
  申请人：UNIV CALIFORNIA

  公开号：WO2021086962A1

  公开（公告）日：2021-05-06

  Methods, kits, and compositions are described for the detection and treatment of premalignant lesions. This early detection allows patients to avoid the risks associated with repetitive imaging often employed to seek differentiation between developing cancer and inflammation. The method comprises (a) administering to the subject a radiographic tracer for a sodium/glucose cotransporter (SGLT); (b) performing a radiographic detection scan of the subject; and (c) detecting signal emitted by the tracer taken up in the scanned subject, whereby detected signal in the subject is indicative of a pre-malignant lesion. In some embodiments, the method further comprises administering an inhibitor of sodium-glucose transporter 2 (SGLT2), such as gliflozin, to a subject in whom a pre-malignant lesion has been detected. In some embodiments, the pre-malignant lesion is in tissue that expresses SGLT2, such as a lung, prostate, bladder, breast, or pancreatic lesion.